Table 4.
Treatment sequences of mold-active triazole (MAT) therapies during the study (FAS)
| Total (N = 1993) | |
|---|---|
| MAT monotherapy, n (%) | 1541 (77.3) |
| Isavuconazole | 510 (25.6) |
| Posaconazole | 540 (27.1) |
| Voriconazole | 491 (24.6) |
| Multiple/sequenced MAT therapies, n (%) | 452 (22.7) |
| Voriconazole-posaconazole | 66 (3.3) |
| Voriconazole-isavuconazole | 54 (2.7) |
| Posaconazole-voriconazole | 52 (2.6) |
| Isavuconazole-posaconazole | 46 (2.3) |
| Isavuconazole-voriconazole | 46 (2.3) |
| Posaconazole-isavuconazole | 44 (2.2) |
| Posaconazole-voriconazole-posaconazole | 26 (1.3) |
| Posaconazole-isavuconazole-posaconazole | 21 (1.1) |
| Isavuconazole-posaconazole-isavuconazole | 18 (0.9) |
| Voriconazole-posaconazole-isavuconazole | 15 (0.8) |
| Isavuconazole-voriconazole-isavuconazole | 13 (0.7) |
| Voriconazole-posaconazole-voriconazole | 10 (0.5) |
| Isavuconazole-voriconazole-posaconazole | 9 (0.5) |
| Posaconazole-voriconazole-isavuconazole | 9 (0.5) |
| Voriconazole-isavuconazole-voriconazole | 9 (0.5) |
| Voriconazole-isavuconazole- posaconazole | 7 (0.4) |
| Isavuconazole-posaconazole-voriconazole | 5 (0.3) |
| Posaconazole-isavuconazole-voriconazole | 2 (0.1) |
The ‘total’ study population includes patients who received prophylaxis and/or treatment at index/enrollment. ‘Prophylaxis’ represents all primary and secondary prophylactic use of MAT, and ‘treatment’ represents all pre-emptive, empiric, targeted, and salvage use of MAT. Monotherapy was assigned to patients receiving one therapy throughout the study. Treatment pattern is reported up to third-line therapy; patients receiving more than three therapies are counted under the sequence corresponding to their first three therapies
FAS full analysis set